ATMOSPHERE: Heart Failure Trial Poisoned By Controversy

–Aliskiren raised regulatory pandemonium as it crashed in trials When it comes to interrupting the renin-angiotensin system, the third time was definitely not the charm. Following the enormous success of the ACE inhibitors and angiotensin-receptor blockers, there were early high expectations for a third class of drugs, the direct renin inhibitors. Those hopes were dashed...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Tags: Heart Failure People, Places & Events Policy & Ethics aliskiren Novartis renin inhibitor Renin-angiotensin system Tekturna Source Type: blogs